So-called checkpoint proteins on immune cells serve as gatekeepers that are supposed to keep foreign invaders from entering healthy cells. Certain cancers use these checkpoints to avoid detection.

In a small phase II trial, radiation-free treatment with pembrolizumab (Keytruda) and platinum-based chemotherapy alone ...

University of Queensland researcher Arutha Kulasinghe studied lung biopsies from the tumours of almost 250 patients with ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new research from more than 100 ...

Sue McCarthy shares her experience overcoming stage 3B lung cancer, reflecting on the impact of her diagnosis. After ...

Merck MRK holds a strong foothold in the oncology space, propelled by its blockbuster PD-L1 inhibitor, Keytruda. The ...

Global Phase III trial has enrolled and randomised over 170 patients, reaching an important milestone as this is above the amount needed to ...

The F.D.A. approved Merck’s injected version of its blockbuster infusion Keytruda. The company says it will be quicker and easier, but it stands to slow the adoption of cheaper competitors and ...

Hamlin was given the treatment as part of a clinical trial after receiving a diagnosis of melanoma last year. She recently ...

Wall Street analysts expect the subcutaneous version of Keytruda, which just launched last week, to help soften the blow when ...

Patients can now receive treatment in as little as one to two minutes, compared to a 30-minute IV infusion New option offers greater convenience and flexibility in treatment settings, from hospitals ...